Novel BCR-ABL1 fusion and leukemic mutations of SETBP1, PAX5, and TP53 detected by next generation sequencing in chronic myeloid leukemia

Patients with BCR-ABL1 fusion genes are potential candidates for targeted therapy with tyrosine kinase inhibitor (TKI) imatinib. However, novel BCR-ABL1 fusion variants can be undetected by qRT-PCR-based routine molecular screening, affecting immediate patient management and proper treatment selecti...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Biol Ther
Main Authors: Fu, Shuang, Hu, Yanping, Fu, Yu, Chen, Fang, Liu, Xuan, Zhang, Minyu, Wang, Xiaohui, Tu, Shichun, Zhang, Jihong
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2016
Assuntos:
Bedside to Bench Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5079385/
https://ncbi.nlm.nih.gov/pubmed/27611742
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2016.1219821
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados